Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 139

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 139
---
. The patent application
relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of psilocybin. The patent application
provides pharmaceutical compositions and combinations comprising psilocybin and N-acylethanolamines, for example, Palmitoylethanolamide
(“ PEA”) and methods for their use in a variety of indications amenable to treatment, including, but not limited to substance
addiction and dependence.

Compositions comprising N, N-DIMETHYLTRYPTAMINE
and N-acylethanolamines and uses thereof is a patent family filed on February 10, 2023, as part of our cooperation agreement with SciSparc.
The patent application relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of N, N-dimethyltryptamine.
The patent application provides pharmaceutical compositions and combinations comprising N, N-dimethyltryptamine and N-acylethanolamines
for example, Palmitoylethanolamide (PEA) and methods for their use in a variety of indications amenable to treatment with N, Ndimethyltryptamine,
including, but not limited to cerebral ischemia and hypoxia.

Compositions comprising 5-METHOXY-2-AMINOINDAN
for treatment of depression is a patent family filed on March 29, 2023. The patent application relates to compositions and methods for
treatment of depression. The patent application provides pharmaceutical compositions comprising 5-methoxy-2-aminoindan (“ MEAI”)
and methods for their use in treatment of depression.

COMPOSITIONS AND METHODS FOR TREATING EATING DISORDERS
is a pending provisional application directed to treating eating disorders with 3-MMC. If converted to a nonprovisional, the 20 year term
for this family ends on March 20, 2045.

5-methoxy-2-aminoindan is a pending provisional
application directed to methods for treating metabolic syndrome using 5-methoxy-2-aminoindan. If converted to a nonprovisional, the 20
year term for this family ends on July 8, 2045.

With respect to the aforementioned provisional
patent applications, we intend to decide whether to file non-provisional patent applications at some time before each application lapses
(for each, within one year of their filing date).

We intend to seek additional patents for its